Register Now: Beyond EDC: Designing a Connected Data Strategy for Predictive Clinical Development
News|Videos|September 23, 2024

The Use of Artificial Intelligence in Clinical Trial Enrollment

In an interview with Applied Clinical Trials Associate Editor Don Tracy, Sonia Lwoff, director, clinical operations, Rho, discusses the potential for artificial intelligence in clinical trial decision-making and enrollment.

ACT: Is there any potential for the use of AI when it comes to decision-making and enrollment?

Lwoff: In the trial development process, AI algorithms can analyze existing data to predict trial outcomes and identify optimal trial designs. It's already occurring and when it comes to patient recruitment and enrollment, AI can accelerate recruitment efforts by analyzing electronic health records and other data sources to identify potential participants who may meet the eligibility criteria for one trial. It's already occurring and when it comes to patient recruitment and enrollment, AI can accelerate recruitment efforts by analyzing electronic health records and other data sources to identify potential participants who may meet the eligibility criteria for one trial. Some site networks are already working with AI to check on their medical records to identify patients. However, we need to be mindful of how this data is being used at hospitals. There are some data privacy considerations. AI can process also and analyze data in real time and detect anomalies and potential issues more quickly than the traditional methods. Last but not least, AI may also be used to analyze previous trials data to start using it for site selection and to predict which sites may perform optimally in a given trial based on the previous experience with those sites.


Related to this article

Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
What Needs to Happen Beyond the Clinical Trial Modernization Act
In this video interview, Kent Thoelke, CEO of Paradigm Health, calls for safe harbor protections, CMS reimbursement safeguards, and funding mechanisms modeled on EHR meaningful use to help community and rural institutions participate in research on par with academic centers.